CRISPR Therapeutics AG CEO Samarth Kulkarni's 2021 pay jumps 87% to $17M
CRISPR Therapeutics AG reports 2021 executive compensation
By ExecPay News
Published: April 25, 2022
CRISPR Therapeutics AG reported fiscal year 2021 executive compensation information on April 25, 2022.
In 2021, six executives at CRISPR Therapeutics AG received on average a compensation package of $7.5M, a 73% increase compared to previous year.
Average pay of disclosed executives at CRISPR Therapeutics AG
Samarth Kulkarni, Chief Executive Officer, received $17M in total, which increased by 87% compared to 2020. 64% of Kulkarni's compensation, or $11M, was in option awards. Kulkarni also received $588K in non-equity incentive plan, $670K in salary, $4.8M in stock awards, as well as $4.5K in other compensation.
Brendan Smith, Chief Financial Officer, received a compensation package of $7.3M. 77% of the compensation package, or $5.6M, was in option awards.
Tony W. Ho, Former EVP, Research and Development, earned $6.5M in 2021, a 68% increase compared to previous year.
Lawrence O. Klein, Chief Operating Officer, received $6M in 2021, which increases by 63% compared to 2020.
James R. Kasinger, General Counsel, earned $4.6M in 2021, a 79% increase compared to previous year.
Michael J. Tomsicek, Chief Financial Officer, received $3.8M in 2021, which increases by 43% compared to 2020.
Related executives
Samarth Kulkarni
CRISPR Therapeutics AG
Chief Executive Officer
Brendan Smith
CRISPR Therapeutics AG
Chief Financial Officer
James Kasinger
CRISPR Therapeutics AG
General Counsel
Lawrence Klein
CRISPR Therapeutics AG
Chief Operating Officer
Tony Ho
CRISPR Therapeutics AG
Former EVP, Research and Development
Michael Tomsicek
CRISPR Therapeutics AG
Chief Financial Officer
You may also like
Source: SEC filing on April 25, 2022.